Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
9 lessons
9mResearchAdvanced
Retatrutide and Body Composition: Why the Real Story Is Adherence, Not Just Scale Weight
The best metabolic tools do more than move the scale. They change how easy it is to follow the plan on day 3, day 30, and day 300.
8mResearchAdvanced
Retatrutide and Food Noise: Why Appetite Control Changes Adherence
The scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.
8mResearchAdvanced
Retatrutide and Visceral Fat: Why the Scale Misses the Real Signal
Scale weight is noisy. If you are using retatrutide, waist trend, body composition, protein intake, and strength matter more than a single weigh-in.
9mPeptidesIntermediate
Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means
Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.
9mPeptidesIntermediate
MOTS-c Enters Phase 2a Human Trial for Prediabetes: What the Research Shows
MOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
10mPeptidesIntermediate
Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard
Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
9mPeptidesIntermediate
MOTS-c: The Mitochondrial Peptide Rewriting Longevity Science
Discovered inside mitochondrial DNA itself, MOTS-c is one of the most fascinating longevity peptides in modern science. It governs how your cells produce energy, fight fat accumulation, and age.
8mPeptidesIntermediate
Retatrutide Phase 3 Results: What the Clinical Data Tells Us
New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.
10mPeptidesIntermediate
Retatrutide: The Triple-Action Weight Loss Peptide Explained
Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.
Also available at /blog for legacy links.